XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2021
Long Term Investment [Abstract]  
Schedule of ownership percentages of investee
    Ownership percentage      
    September 30,     December 31,     Accounting
Name of related party   2021     2020     treatments
Braingenesis Biotechnology Co., Ltd.     0.17 %     0.17 %   Cost Method
Genepharm Biotech Corporation     0.70 %     0.70 %   Cost Method
BioHopeKing Corporation     5.90 %     5.90 %   Cost Method
BioFirst Corporation     15.99 %     15.99 %   Equity Method
Rgene Corporation     31.62 %     31.62 %   Equity Method

 
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

  
Schedule of long-term investment
    September 30,
2021		     December 31,
2020		  
    (Unaudited)        
Non-marketable Cost Method Investments, net            
Braingenesis Biotechnology Co., Ltd.   $ 7,919     $ 7,853  
Genepharm Biotech Corporation     24,177       23,974  
BioHopeKing Corporation     898,068       890,564  
Sub total     930,164       922,391  
Equity Method Investments, net                
BioFirst Corporation     76,369       268,336  
Rgene Corporation    
-
      
-
  
Total   $ 1,006,533     $ 1,190,727  

 
Schedule of balance sheets
    September 30,
2021		     December 31,
2020		  
    (Unaudited)        
Current Assets   $ 1,752,070     $ 1,299,822  
Non-current Assets     2,533,136       2,540,041  
Current Liabilities     2,680,177       1,986,340  
Non-current Liabilities     40,008       73,197  
Stockholders’ Equity     1,565,021       1,780,326  

 

    September 30,
2021		     December 31,
2020		  
    (Unaudited)        
Current Assets   $ 81,599     $ 123,958  
Noncurrent Assets     376,369       412,342  
Current Liabilities     1,765,628       1,392,756  
Noncurrent Liabilities     9,897       38,953  
Shareholders’ Deficit     (1,317,557 )     (895,409 )

 
Schedule of statements of operation
    Nine months Ended
September 30,		  
    2021     2020  
    (Unaudited)  
Net sales   $ 17,451     $ 134,759  
Gross profit     5,414       6,397  
Net loss     (887,230 )     (4,936,294 )
Share of losses from investments accounted for using the equity method     (193,147 )     (1,067,298 )

 

    Nine months Ended
September 30,		  
    2021     2020  
    (Unaudited)  
Net sales   $
-
     $ 16,449  
Gross Profit    
-
       (332,763 )
Net loss     (411,897 )     (441,678 )
Share of loss from investments accounted for using the equity method    
-
      
-
  

 
Schedule of equity investments
    Nine months Ended
September 30,		  
    2021     2020  
    (Unaudited)  
Share of equity method investee losses   $ (193,147 )   $ (1,067,298 )